2164-34-3

Usage

Chemical Properties

Clear colorless to greyish or light yellow liquid

InChI:InChI=1/C9H9BrO2/c10-5-7-6-11-8-3-1-2-4-9(8)12-7/h1-4,7H,5-6H2/t7-/m1/s1

Upstream product

• 4739-94-0 ethyl 2,3-dihydro-1,4-benzodioxin-2-carboxylate 
• 791-28-6 Triphenylphosphine oxide 
• 3663-82-9 2-hydroxymethyl-2,3-dihydrobenzo[1,4]dioxin 
• 1034-39-5 dibromotriphenylphosphorane 

Downstream Products

• 129975-50-4 5-[(2,3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-methyl-amino]-2-(3,4-dimethoxy-phenyl)-2-isopropyl-pentanenitrile 
• 85076-06-8 axamozide 
• 18505-91-4 2-(2,3-Dihydro-1,4-benzodioxin-2-yl)acetonitrile 
• 632-51-9 1,1,2,2-tetraphenylethylene 
• 1126-20-1 2-allyloxyphenol 
• 87086-36-0 2-(2,3-dihydrobenzo[1,4]dioxin-2-yl)ethylamine 

Relevant academic research and scientific papers

Design and synthesis of substituted compounds containing the 1,4- benzodioxin subunit. New potential calcium antagonists

New compounds possessing 1,4-benzodioxin or its saturated analogous heterocyclic system were synthesized and tested for calcium antagonist activity. Biological differences were seen between the different modifications applied. These compounds have been shown to be representative of a novel series of calcium channel antagonists. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

Derivatives of 2-methyl>-1,4-benzodioxan as Orally Active 5-Lipoxygenase Inhibitors

N-Hydroxyureas based on the 1,4-benzodioxan template were prepared from appropriately substituted 1,4-benzodioxan-2-methanols as the key intermediates and evaluated in the in vitro guinea pig polymorphonuclear leukocyte 5-lipoxygenase (5-LO) assay for their 5-LO inhibitory activity.Placement of a 7-phenoxy or 7-p-fluorophenoxy substituent resulted in a dramatic increase in in vitro potency.Selected compounds were subsequently assayed in an ex vivo dog model of LTB4 synthesis at a dose of 1.0 mg/kg.The 7-phenoxy derivatives 16 and 17 showed modest duration of action (DA) in this dog model.The 6-regioisomers 21 and 22 were less potent.Replacement of the 7-phenoxy group of 16 with the p-fluorophenoxy moiety enhanced the DA dramatically.Compound 18 (CGS 25667), which had an IC50 value of 100 nM in the in vitro guinea pig 5-LO assay, had a DA of 8.5 h (zileuton, DA = 8.5 h) at the oral dose of 1.0 mg/kg.Optical antipodes (24, 26) of 18 were independently synthesized in high ( >95percent) enantiomeric purity from commercially available optically active glycidyl tosylates and evaluated.In the in vitro assay, the 2S-(-)-enantiomer (24, CGS, 25997, IC50 = 85 nM) was found to be twice as active as the 2R-(+)-counterpart (26, CGS 25998, IC50 = 180 nM).In the ex vivo experiment, 24, which dose dependently inhibited plasma 5-LO activity, was shown to be significantly longer acting than 26, with a DA of 8.4 h when dosed orally at 1.0 mg/kg.

CERTAIN BENZODIOXOLE, BENZODIOXANE AND BENZODIOXEPIN DERIVATIVES USEFUL AS 5-LIPOXYGENASE INHIBITORS

The invention relates to the compounds of the formula wherein each R independently represents hydrogen, lower alkyl, halogen, trifluoromethyl, lower alkoxy, carbocyclic or heterocyclic aryl, carbocyclic or hetero-cyclic aryloxy, carbocyclic or heterocyclic aryl-lower alkyloxy, carbocyclic or heterocyclic aryl-lower alkyl, C3-C7-cycloalkyl-lower alkyloxy, or Cs-Cv-cycloalk-yloxy; n represents 1, 2, 3 or 4; m represents 0, 1 or 2; A represents a direct bond or lower alkylene; X represents oxygen or sulfur; Ri represents hydrogen, acyl, lower alkoxycarbonyl, aminocarbonyl, mono- or di-lower alkylaminocarbonyl, lower alkenylaminocarbonyl, lower alkynylaminocarbonyl, carbocyclic or heterocy-clic aryl-lower alkylaminocarbonyl, carbocyclic or heterocyclic arylaminocarbonyl, C3-C7-cycloalk-ylaminocarbonyl or C3-C7-cycloalkyl-lower al-kylaminocarbonyl; R2 represents lower alkyl, lower alkoxycarbonyl-lower alkyl, C3-C7-cycloalkyl, carbo-cyclic or heterocyclic aryl, carbocyclic or heterocyclic aryl-lower alkyl, C3-C7-cycloalkyl-lower alkyl, amino, mono- or di-lower alkylamino, lower alkenylamino, lower alkynylamino, carbocyclic or heterocyclic aryl-lower alkylamino, carbocyclic or heterocyclic arylamino, C3-C7-cycloalkylamino, C3-C7-cycloalkyl-lower alkylamino, lower alkoxycarbonyl-lower alkyl-amino or lower alkoxy; R3 and R4 independently repre-sent hydrogen or lower alkyl; and pharmaceuticallyacceptable salts thereof; which are useful as 5-lipoxyge-nase inhibitors.

Neuroleptic n-oxacyclyl-alkylpiperidine derivatives

Neuroleptically active compounds of the formula STR1 wherein R6 and R10 are --H or CH3 ; R7 and R8 are independently --H, --F, --Cl, or --CH3 ; and R9 is --F, --Cl, --CH3, or --OCH3.

9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones

Compounds useful in the prevention and/or treatment of hypertension, congestive heart failure, arrhythmia, migraine, vasospastic disorders, and asthma are represented by the formula: STR1 wherein: R1 is STR2 R2, R3, and R4 are independently hydrogen or lower alkyl of one to four carbon atoms; X is hydrogen, lower alkyl of one to four carbon atoms, lower alkoxy of one to four carbon atoms or halo; m is 1 or 2; and n is 1, 2 or 3; and the pharmaceutically acceptable acid addition salts thereof.